Aims and scope
European Journal of Gynaecological Oncology (EJGO) is an international, peer-reviewed, open access journal. EJGO publishes on a broad range of gynaecologic oncology topics. Different types of articles are considered for publication (see Aims & Scope) with emphasis on original research to include prospective clinical trials, basic and applied science, case-control, and cohort studies. We also encouraged the submission of systematic reviews and meta-analyses.
Articles
Ovarian Cancer Immunotherapy en Route: IL9 Inhibits Growth of Ovarian Cancer and Upregulates its Expression of Ox40L and 4-1BBL
Ovarian Cancer Immunotherapy en Route: IL9 Inhibits Growth of Ovarian Cancer and Upregulates its Expression of Ox40L and 4-1BBL
DOI: 10.31083/j.ejgo4302021
Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer?
Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer?
DOI: 10.31083/j.ejgo4302022
Complete blood count parameters, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in hydatidiform mole versus missed abortion
Complete blood count parameters, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in hydatidiform mole versus missed abortion
DOI: 10.31083/j.ejgo4302023
Identifying and overcoming a mechanism of resistance to WEE1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells
Identifying and overcoming a mechanism of resistance to WEE1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells
DOI: 10.31083/j.ejgo4302024
Utility of Intraoperative Frozen Section of the Inguinofemoral Sentinel Lymph Node in Vulvar Cancer: A Retrospective Cohort
Utility of Intraoperative Frozen Section of the Inguinofemoral Sentinel Lymph Node in Vulvar Cancer: A Retrospective Cohort
DOI: 10.31083/j.ejgo4302025
BRCA screening, treatment patterns and response among patients with
ovarian cancer in the second line treatment setting: results from a real world survey
BRCA screening, treatment patterns and response among patients with
ovarian cancer in the second line treatment setting: results from a real world survey
DOI: 10.31083/j.ejgo4302026
A Performance Evaluation of an Optoelectronic Cervical Screening Device in Comparison to Cytology and HPV DNA Testing
A Performance Evaluation of an Optoelectronic Cervical Screening Device in Comparison to Cytology and HPV DNA Testing
DOI: 10.31083/j.ejgo4302027
Adjuvant radiotherapy of endometrial cancer: role of 18F-FDG-PET/CT in treatment modulation
Adjuvant radiotherapy of endometrial cancer: role of 18F-FDG-PET/CT in treatment modulation
DOI: 10.31083/j.ejgo4302028
(This article belongs to the Special Issue Endometrial Cancer)
The expression and prognostic value of minichromosome maintenance markers in human breast cancer: a comprehensive analysis
The expression and prognostic value of minichromosome maintenance markers in human breast cancer: a comprehensive analysis
DOI: 10.31083/j.ejgo4302029
Effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer
Effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer
DOI: 10.31083/j.ejgo4302030
Identification of hypoxia-related prognostic signature for ovarian cancer based on Cox regression model
Identification of hypoxia-related prognostic signature for ovarian cancer based on Cox regression model
DOI: 10.31083/j.ejgo4302031
Interaction of Pten gene and AKT/mTOR pathway in endometrial adenocarcinoma proliferation
Interaction of Pten gene and AKT/mTOR pathway in endometrial adenocarcinoma proliferation
DOI: 10.31083/j.ejgo4302033
Expression and Analysis of Rsf-1 and P16 in Cervical Intraepithelial Neoplasia
Expression and Analysis of Rsf-1 and P16 in Cervical Intraepithelial Neoplasia
DOI: 10.31083/j.ejgo4302034
Evaluation of tumor size in cervix cancer patients treated with surgery: ultrasonography or MRI?
Evaluation of tumor size in cervix cancer patients treated with surgery: ultrasonography or MRI?
DOI: 10.31083/j.ejgo4302035
Educational programs for post-treatment breast cancer survivors: a systematic review
Educational programs for post-treatment breast cancer survivors: a systematic review
DOI: 10.31083/j.ejgo4302036
(This article belongs to the Special Issue Systematic Review or Meta-Analysis in Gynaecological Oncology)
The association between HIC1 methylation and ovarian cancer: a meta-analysis
The association between HIC1 methylation and ovarian cancer: a meta-analysis
DOI: 10.31083/j.ejgo4302037
Research Trends in the Early Diagnosis of Ovarian Cancer during 2001–2020: A Bibliometric Analysis
Research Trends in the Early Diagnosis of Ovarian Cancer during 2001–2020: A Bibliometric Analysis
DOI: 10.31083/j.ejgo4302038
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Advanced Ovarian Cancer. A Literature Review
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Advanced Ovarian Cancer. A Literature Review
DOI: 10.31083/j.ejgo4302039
(This article belongs to the Special Issue Radical Surgery in Ovarian Cancer)
Treatment Progress in Triple Negative Breast Cancer
Treatment Progress in Triple Negative Breast Cancer
DOI: 10.31083/j.ejgo4302040
(This article belongs to the Special Issue Breast Cancer)
Management of malignant dysgerminoma of the ovary
Management of malignant dysgerminoma of the ovary
DOI: 10.31083/j.ejgo4302041
(This article belongs to the Special Issue Systematic Review or Meta-Analysis in Gynaecological Oncology)
Uterine lipoleiomyoma: a benign entity with malignant transformation potential?
Uterine lipoleiomyoma: a benign entity with malignant transformation potential?
DOI: 10.31083/j.ejgo4302042
CRS and HIPEC in a patient with recurrent ovarian cancer after PDS and adjuvant chemotherapy, a case report and MDT discussion
CRS and HIPEC in a patient with recurrent ovarian cancer after PDS and adjuvant chemotherapy, a case report and MDT discussion
DOI: 10.31083/j.ejgo4302043
(This article belongs to the Special Issue Hyperthermic Intraperitoneal Chemotherapy to Gynaecological Oncology)
Published Ahead of Print
Inquiry and Endometrial-Online computer program: 27 years of clinical registry for endometrial cancer at the University Medical Centre Maribor
Inquiry and Endometrial-Online computer program: 27 years of clinical registry for endometrial cancer at the University Medical Centre Maribor
Online publish date: 24 April 2022
DOI: 10.22514/ejgo.2022.001
Successful management of metastatic ovarian carcinosarcoma with olaparib plus bevacizumab: a case report
Successful management of metastatic ovarian carcinosarcoma with olaparib plus bevacizumab: a case report
Online publish date: 24 April 2022
DOI: 10.22514/ejgo.2022.002
Surgical management in the pelvis for patients with advanced ovarian cancer
Surgical management in the pelvis for patients with advanced ovarian cancer
Online publish date: 24 April 2022
DOI: 10.22514/ejgo.2022.003
Short and long-term outcomes of endometrial cancer and atypical endometrial hyperplasia management in young women
Short and long-term outcomes of endometrial cancer and atypical endometrial hyperplasia management in young women
Online publish date: 24 April 2022
DOI: 10.22514/ejgo.2022.004
Pretreatment anemia status and elevated PLR affect the prognosis of locally advanced cervical squamous cell carcinoma patients treated with concurrent chemoradiotherapy
Pretreatment anemia status and elevated PLR affect the prognosis of locally advanced cervical squamous cell carcinoma patients treated with concurrent chemoradiotherapy
Online publish date: 24 April 2022
DOI: 10.22514/ejgo.2022.005
Special Issues
Topic Collection "Current Novel Treatment of Patients with Ovarian Cancer"
Keywords: Ovarian Cancer, Epithelial Ovarian Cancer, Optimal Debulking Surgery, Chemotherapy HIPEC, Platinum-resistant Ovarian Cancer, Anti-angiogenesis, PARP Inhibitors
Editor: Samir A. Farghaly, MD, PhD,Scott M. Eisenkop, MD
Submission deadline: 31 December 2022
Breast Cancer
Keywords: Breast cancer;Systemic treatment;Adjuvant setting;Metastatic setting;Genetic councelling;Triple negative breast cancer;Her2+ Breast cancer;Endocrine treatment
Editor: Michael Friedrich, MD,Nicolò Bertozzi, MD
Submission deadline: 30 April 2022
Systematic Review or Meta-Analysis in Gynaecological Oncology
Keywords: Cervical cancer;Ovarian cancer;Uterine/endometrial cancer;Vulvar cancer;Vaginal cancer;Breast cancer;Gestational trophoblastic disease;Primary peritoneal cancer
Editor: Enrique Hernandez, MD
Submission deadline: 25 April 2022
Gynecological tumor genomics
Keywords: Gynecological Tumor; Genomics; Transcriptomics; Bioinformatics
Editor: Xinhua Liu, PhD
Submission deadline: 01 January 2023
Frontiers in endometrial, cervical and ovary cancers
Keywords: Endometrial Cervical; Ovarian Cancers; Diagnosis; Immunotherapy, Targeting Therapy
Editor: Prof. Qilian Liang,Associate Prof. Xiangning Zhang, MD, PhD
Submission deadline: 28 February 2023
Prognostic Models Based on Machine Learning for Gynecological Cancers
Keywords: Bioinformatics; Machine Learning; Signature; Prognostic Models; Gynecological Cancers
Editor: Jiang Feng, MD
Submission deadline: 31 January 2023
Treatment of advanced gynecological malignancies
Keywords: Advanced; Cervical Cancer; Ovarian Cancer; Endometrial Cancer; Immunotherapy; Resistance; Targeted Therapy
Editor: Jinhui Liu, PhD
Submission deadline: 31 December 2022
Triple Negative Breast Cancer
Keywords: Triple negative breast cancer
Editor: Patrick Neven, MD
Submission deadline: 31 March 2022
Safe Minimally Invasive Radical Hysterectomy in Early-Stage Cervical Cancer
Keywords: Uterine Cervical Neoplasms;Minimally Invasive Surgical Procedures;Radical Hysterectomy
Editor: Tae-Wook Kong, MD
Submission deadline: 31 March 2022
Molecular Markers in Ovarian Cancer: Roles in Diagnosis, Prognostic Prediction, and Personalized Therapy
Keywords: Ovarian Cancer;Diagnosis;Prognosis;Treatment Response;Personalized Therapy;Platinum Resistance;Homologous Recombination Deficiency;Immunotherapy;Cytoreduction;Proteomics;Genomics;Prognostic Biomarkers;Diagnostic Biomarkers
Editor: Sharad Ghamande, MD,David Mysona, MD
Submission deadline: 30 March 2022
Featured Article
Real-world bevacizumab utilization and outcomes among women with ovarian cancer in Europe and the United States. DOI: 10.31083/j.ejgo4206181
To Be a Reviewer
If you would like to volunteer to review a manuscript for European Journal of Gynaecological Oncology journal, please click “Review for EJGO” below to register at our submission website or log in our Online Peer Review system. Your name, contact details, and expertise will be automatically added to our database of reviewers.
Review for EJGOJoin Editorial Board
You are welcome to join our editorial board. Our journal produces and issues editorial board certificates for editorial board members, and the journal website will display the names and personal websites of editorial board members to help enhance their scientific influence. Members of the editorial committee are entitled to 1 free publication (both editorial member’s or recommended paper) per year, and other articles over 2 can enjoy 30% discount of publishing fee.
Join Editorial BoardEditor-in-Chief
Professor Enrique Hernandez, MD, FACOG, FACS.
Dr. Hernandez is the J. Robert Willson Professor and Chair, Obstetrics, Gynecology and Reproductive Sciences of Lewis Katz School of Medicine at Temple University. He is also a professor in Pathology and Laboratory Medicine of Lewis Katz School of Medicine at Temple University. He specializes in comprehensive, compassionate care of women with gynecologic cancer and pre-cancerous conditions, using the most up-to-date and sophisticated diagnostic and treatment tools.